Comments
Hyderabad-based Bharat Biotech on Friday received approval from the Drugs Controller General of India (DCGI) for Phase 3 clinical trials of its intranasal vaccine BBV154 against Covid 19.
According to reports, the trials will be conducted at nine different sites — Atman Hospital, Ahmedabad, Gujarat; AIIMS, Delhi and Patna; Oyster and Pearls Hospitals, Pune; Pt.BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana; Acharya Vinobha Bhave Rural Hospital, Wardha; Jeevan Rekha Hospital, Belagavi; Rana hospital, Gorakhpur; and Prakhar Hospital, Uttar Pradesh.
The Subject Expert Committee of the Central Drugs Control Standard Organization (CDSCO) in the last meeting had recommended clinical trials of nasal vaccine. The trials will evaluate the nasal vaccine for both the two dose primary schedule, and booster dose schedule. Intranasal vaccines can be easily administered without having to train healthcare workers.
Related Stories
Covaxin, Covishiled get conditional market authorisation from DCGI
No decision has been taken on the price capping yetThe DCGI on Thursday had also given conditional market approval to the Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin for use in the adult population.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.